164 related articles for article (PubMed ID: 15073758)
1. Adverse drug reaction monitoring--cost and benefit considerations. Part II: cost and preventability of adverse drug reactions leading to hospital admission.
Goettler M; Schneeweiss S; Hasford J
Pharmacoepidemiol Drug Saf; 1997 Oct; 6 Suppl 3():S79-90. PubMed ID: 15073758
[TBL] [Abstract][Full Text] [Related]
2. Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations.
Rottenkolber D; Schmiedl S; Rottenkolber M; Farker K; Saljé K; Mueller S; Hippius M; Thuermann PA; Hasford J;
Pharmacoepidemiol Drug Saf; 2011 Jun; 20(6):626-34. PubMed ID: 21384463
[TBL] [Abstract][Full Text] [Related]
3. Adverse drug reactions in a department of systemic diseases-oriented internal medicine: prevalence, incidence, direct costs and avoidability.
Lagnaoui R; Moore N; Fach J; Longy-Boursier M; Bégaud B
Eur J Clin Pharmacol; 2000 May; 56(2):181-6. PubMed ID: 10877014
[TBL] [Abstract][Full Text] [Related]
4. Frequency, types, severity, preventability and costs of Adverse Drug Reactions at a tertiary care hospital.
Geer MI; Koul PA; Tanki SA; Shah MY
J Pharmacol Toxicol Methods; 2016; 81():323-34. PubMed ID: 27109493
[TBL] [Abstract][Full Text] [Related]
5. Adverse drug reaction monitoring--cost and benefit considerations. Part I: frequency of adverse drug reactions causing hospital admissions.
Muehlberger N; Schneeweiss S; Hasford J
Pharmacoepidemiol Drug Saf; 1997 Oct; 6 Suppl 3():S71-7. PubMed ID: 15073757
[TBL] [Abstract][Full Text] [Related]
6. Frequency and cost of serious adverse drug reactions in a department of general medicine.
Moore N; Lecointre D; Noblet C; Mabille M
Br J Clin Pharmacol; 1998 Mar; 45(3):301-8. PubMed ID: 9517375
[TBL] [Abstract][Full Text] [Related]
7. Adverse drug reactions, multimorbidity and polypharmacy: a prospective analysis of 1 month of medical admissions.
Osanlou R; Walker L; Hughes DA; Burnside G; Pirmohamed M
BMJ Open; 2022 Jul; 12(7):e055551. PubMed ID: 35788071
[TBL] [Abstract][Full Text] [Related]
8. Adverse drug reactions in an elderly hospitalised population: inappropriate prescription is a leading cause.
Passarelli MC; Jacob-Filho W; Figueras A
Drugs Aging; 2005; 22(9):767-77. PubMed ID: 16156680
[TBL] [Abstract][Full Text] [Related]
9. Costs associated with adverse drug reactions in an older population admitted to hospital: a prospective cohort study.
Bennett K; Cahir C; Sorensen J
Eur J Clin Pharmacol; 2023 Oct; 79(10):1417-1424. PubMed ID: 37615688
[TBL] [Abstract][Full Text] [Related]
10. [Systematic review of studies assessing the cost of adverse drug reactions].
Vallano Ferraz A; Agustí Escasany A; Pedrós Xolvi C; Arnau de Bolós JM
Gac Sanit; 2012; 26(3):277-83. PubMed ID: 22152925
[TBL] [Abstract][Full Text] [Related]
11. Readmissions and adverse drug reactions in internal medicine: the economic impact.
Dormann H; Neubert A; Criegee-Rieck M; Egger T; Radespiel-Tröger M; Azaz-Livshits T; Levy M; Brune K; Hahn EG
J Intern Med; 2004 Jun; 255(6):653-63. PubMed ID: 15147529
[TBL] [Abstract][Full Text] [Related]
12. Adverse Drug reactions in an Ageing PopulaTion (ADAPT) study protocol: a cross-sectional and prospective cohort study of hospital admissions related to adverse drug reactions in older patients.
Cahir C; Curran C; Byrne C; Walsh C; Hickey A; Williams DJ; Bennett K
BMJ Open; 2017 Jun; 7(6):e017322. PubMed ID: 28600381
[TBL] [Abstract][Full Text] [Related]
13. Admissions to a medical intensive care unit related to adverse drug reactions.
Rivkin A
Am J Health Syst Pharm; 2007 Sep; 64(17):1840-3. PubMed ID: 17724366
[TBL] [Abstract][Full Text] [Related]
14. Hospital admissions resulting from preventable adverse drug reactions.
McDonnell PJ; Jacobs MR
Ann Pharmacother; 2002 Sep; 36(9):1331-6. PubMed ID: 12196047
[TBL] [Abstract][Full Text] [Related]
15. Drug-induced blood consumption: the impact of adverse drug reactions on demand for blood components in German departments of internal medicine.
Rottenkolber D; Schmiedl S; Rottenkolber M; Thuermann PA; Hasford J
Basic Clin Pharmacol Toxicol; 2012 Oct; 111(4):240-7. PubMed ID: 22487717
[TBL] [Abstract][Full Text] [Related]
16. Adverse drug reaction monitoring in a secondary care hospital in South India.
Arulmani R; Rajendran SD; Suresh B
Br J Clin Pharmacol; 2008 Feb; 65(2):210-6. PubMed ID: 17662089
[TBL] [Abstract][Full Text] [Related]
17. Assessing the feasibility of using an adverse drug reaction preventability scale in clinical practice: a study in a French emergency department.
Olivier P; Boulbés O; Tubery M; Lauque D; Montastruc JL; Lapeyre-Mestre M
Drug Saf; 2002; 25(14):1035-44. PubMed ID: 12408734
[TBL] [Abstract][Full Text] [Related]
18. Pediatric hospital admission due to adverse drug reactions: Report from a tertiary center.
Gholami K; Babaie F; Shalviri G; Javadi MR; Faghihi T
J Res Pharm Pract; 2015; 4(4):212-5. PubMed ID: 26645028
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the direct cost of adverse drug reactions in hospitalised patients.
Bordet R; Gautier S; Le Louet H; Dupuis B; Caron J
Eur J Clin Pharmacol; 2001 Mar; 56(12):935-41. PubMed ID: 11317484
[TBL] [Abstract][Full Text] [Related]
20. The economic burden of preventable adverse drug reactions: a systematic review of observational studies.
Formica D; Sultana J; Cutroneo PM; Lucchesi S; Angelica R; Crisafulli S; Ingrasciotta Y; Salvo F; Spina E; Trifirò G
Expert Opin Drug Saf; 2018 Jul; 17(7):681-695. PubMed ID: 29952667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
